发布求助
文献互助 智能选刊 最新文献

Alimentary Pharmacology & Therapeutics最新文献

筛选
英文 中文
Correction to “Meta‐Analysis: Enhanced Liver Fibrosis (ELF) Test for Identifying Significant Fibrosis, Advanced Fibrosis, and Cirrhosis in Patients with Metabolic Dysfunction‐Associated Steatotic Liver Disease” 修正“荟萃分析：增强肝纤维化（ELF）测试用于识别代谢功能障碍相关脂肪变性肝病患者的显著纤维化、晚期纤维化和肝硬化”
IF 7.6 1区 医学
Alimentary Pharmacology & Therapeutics Pub Date : 2026-10-20 DOI: 10.1111/apt.71051
{"title":"Correction to “Meta‐Analysis: Enhanced Liver Fibrosis (ELF) Test for Identifying Significant Fibrosis, Advanced Fibrosis, and Cirrhosis in Patients with Metabolic Dysfunction‐Associated Steatotic Liver Disease”","authors":"","doi":"10.1111/apt.71051","DOIUrl":"https://doi.org/10.1111/apt.71051","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"8 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149226376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial: “Host Innate Immunity Reaches the Clinic—The Laboratory of Genetics and Physiology Protein 2 (LGP2) Q425R Variant and Severity of Chronic Hepatitis Delta: Authors' Reply” 社论：《宿主先天免疫进入临床——遗传与生理蛋白2 (LGP2) Q425R变异与慢性丁型肝炎严重程度实验室：作者回复》
IF 7.6 1区 医学
Alimentary Pharmacology & Therapeutics Pub Date : 2026-10-20 DOI: 10.1111/apt.71065
Sara Cmet, Edmondo Falleti, Elisabetta Degasperi, Pietro Lampertico, Pierluigi Toniutto
{"title":"Editorial: “Host Innate Immunity Reaches the Clinic—The Laboratory of Genetics and Physiology Protein 2 (LGP2) Q425R Variant and Severity of Chronic Hepatitis Delta: Authors' Reply”","authors":"Sara Cmet, Edmondo Falleti, Elisabetta Degasperi, Pietro Lampertico, Pierluigi Toniutto","doi":"10.1111/apt.71065","DOIUrl":"https://doi.org/10.1111/apt.71065","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"163 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149221393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial: Taking a Different Route–Navigating the Switch From Intravenous to Subcutaneous Vedolizumab. Authors' Reply 社论：采取不同的路线-引导从静脉注射到皮下注射的Vedolizumab的转换。作者的回复
IF 7.6 1区 医学
Alimentary Pharmacology & Therapeutics Pub Date : 2026-10-20 DOI: 10.1111/apt.71069
Marianne Hupé, Xavier Roblin, David Laharie
{"title":"Editorial: Taking a Different Route–Navigating the Switch From Intravenous to Subcutaneous Vedolizumab. Authors' Reply","authors":"Marianne Hupé, Xavier Roblin, David Laharie","doi":"10.1111/apt.71069","DOIUrl":"https://doi.org/10.1111/apt.71069","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"38 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149221332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter: Moving Beyond the Biopsy in Eosinophilic Oesophagitis: A Goal, But Not Yet a Reality. Authors' Reply 嗜酸性粒细胞性食管炎的活检：一个目标，但尚未实现。作者的回复
IF 7.6 1区 医学
Alimentary Pharmacology & Therapeutics Pub Date : 2026-10-20 DOI: 10.1111/apt.71068
Pierfrancesco Visaggi, Edoardo Vincenzo Savarino, Nicola de Bortoli
{"title":"Letter: Moving Beyond the Biopsy in Eosinophilic Oesophagitis: A Goal, But Not Yet a Reality. Authors' Reply","authors":"Pierfrancesco Visaggi, Edoardo Vincenzo Savarino, Nicola de Bortoli","doi":"10.1111/apt.71068","DOIUrl":"https://doi.org/10.1111/apt.71068","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"30 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149221334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial: Evolving Models for Hepatocellular Carcinoma Prognostication 编辑：不断发展的肝细胞癌预后模型
IF 7.6 1区 医学
Alimentary Pharmacology & Therapeutics Pub Date : 2026-10-19 DOI: 10.1111/apt.71056
Rex Wan‐Hin Hui, James Fung
{"title":"Editorial: Evolving Models for Hepatocellular Carcinoma Prognostication","authors":"Rex Wan‐Hin Hui, James Fung","doi":"10.1111/apt.71056","DOIUrl":"https://doi.org/10.1111/apt.71056","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"11 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149218458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter: LGP2 Q425R in Chronic Hepatitis Delta—Allele Dose, Hepatic Steatosis and Prior Interferon Exposure 信函：LGP2 Q425R与慢性肝炎δ等位基因剂量、肝脂肪变性和既往干扰素暴露有关
IF 7.6 1区 医学
Alimentary Pharmacology & Therapeutics Pub Date : 2026-10-17 DOI: 10.1111/apt.71059
Yakup Demir
{"title":"Letter: LGP2 Q425R in Chronic Hepatitis Delta—Allele Dose, Hepatic Steatosis and Prior Interferon Exposure","authors":"Yakup Demir","doi":"10.1111/apt.71059","DOIUrl":"https://doi.org/10.1111/apt.71059","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"33 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence and Risk Factors for C. difficile Reinfection After Faecal Microbiota Transplantation or Antibiotic Therapy 粪便菌群移植或抗生素治疗后艰难梭菌再感染的发生率和危险因素
IF 7.6 1区 医学
Alimentary Pharmacology & Therapeutics Pub Date : 2026-10-17 DOI: 10.1111/apt.71035
C. R. Kelly, B. J. Kelly, Q. Wu, L. Laine, G. D. Wu, A. Kim, L. Fredell, S. Serra, J. D. Lewis
{"title":"Incidence and Risk Factors for C. difficile Reinfection After Faecal Microbiota Transplantation or Antibiotic Therapy","authors":"C. R. Kelly, B. J. Kelly, Q. Wu, L. Laine, G. D. Wu, A. Kim, L. Fredell, S. Serra, J. D. Lewis","doi":"10.1111/apt.71035","DOIUrl":"https://doi.org/10.1111/apt.71035","url":null,"abstract":"Background Faecal microbiota transplant (FMT) is an effective treatment for multiply recurrent <jats:styled-content style=\"fixed-case\"> <jats:italic>C. difficile</jats:italic> </jats:styled-content> infection (mrCDI). Less is known about rates of reinfection after successful FMT. We aimed to estimate the incidence of CDI reinfection, 6 or more months after FMT, to determine whether rates differ between mrCDI treated with and without FMT and whether proton pump inhibitor (PPI) therapy increases the risk of reinfection. Methods Among patients with mrCDI (defined as ≥ 2 recurrences after the initial CDI episode) we compared reinfection with CDI (defined as a first recurrence &gt; 183 days after treatment completion) in patients who underwent antibiotics followed by FMT with those treated with antibiotics alone in Optum's de‐identified Clinformatics Data Mart Database (OPTUM CDM). We also compared reinfection between those with and without PPI use in OPTUM CDM and the American Gastroenterological Association FMT Registry. Results In OPTUM CDM, 6384 patients treated with antibiotics alone and 1786 with antibiotics + FMT met inclusion criteria (median follow‐up 704 days). One‐year and 3‐year CDI reinfection incidences were 5% and 10% in the FMT group and 6% and 12% in the antibiotics group: Cox regression HR 0.89, 95% CI 0.73–1.08. PPI use was associated with an increased risk of reinfection following FMT (HR 1.57, 1.03–2.41) in OPTUM CDM and in the FMT Registry (HR 1.62, 95% CI 0.84–3.12). Conclusions CDI reinfection rates are low after successful FMT and similar to rates in patients treated with antibiotics alone. PPI use was associated with reinfection, supporting reassessment of the ongoing indication for PPI therapy in patients with mrCDI.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"21 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149199015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial: How Can We Best Detect Frailty in Older Patients With Inflammatory Bowel Disease? Authors'Reply. 社论：我们如何最好地检测老年炎症性肠病患者的虚弱？作者'Reply。
IF 6.8 1区 医学
Alimentary Pharmacology & Therapeutics Pub Date : 2026-10-16 DOI: 10.1111/apt.71054
Lorena Carballo-Folgoso, José María Duque Alcorta, Pilar Varela, Adolfo Suárez, Sabino Riestra
{"title":"Editorial: How Can We Best Detect Frailty in Older Patients With Inflammatory Bowel Disease? Authors'Reply.","authors":"Lorena Carballo-Folgoso, José María Duque Alcorta, Pilar Varela, Adolfo Suárez, Sabino Riestra","doi":"10.1111/apt.71054","DOIUrl":"https://doi.org/10.1111/apt.71054","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":" ","pages":""},"PeriodicalIF":6.8,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149190097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial: Cardiometabolic Burden and Prognosis in Alcohol‐Related Hepatitis 社论：酒精相关性肝炎的心脏代谢负担和预后
IF 7.6 1区 医学
Alimentary Pharmacology & Therapeutics Pub Date : 2026-10-15 DOI: 10.1111/apt.71053
Fredrik Åberg, Eneli Katunin
{"title":"Editorial: Cardiometabolic Burden and Prognosis in Alcohol‐Related Hepatitis","authors":"Fredrik Åberg, Eneli Katunin","doi":"10.1111/apt.71053","DOIUrl":"https://doi.org/10.1111/apt.71053","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"6 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149172945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter: Moving Beyond the Biopsy in Eosinophilic Esophagitis: A Goal, but Not Yet a Reality 嗜酸性粒细胞性食管炎的活检：一个目标，但尚未实现
IF 7.6 1区 医学
Alimentary Pharmacology & Therapeutics Pub Date : 2026-10-15 DOI: 10.1111/apt.71049
Erin Zisman, Dhyanesh A. Patel
{"title":"Letter: Moving Beyond the Biopsy in Eosinophilic Esophagitis: A Goal, but Not Yet a Reality","authors":"Erin Zisman, Dhyanesh A. Patel","doi":"10.1111/apt.71049","DOIUrl":"https://doi.org/10.1111/apt.71049","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"30 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149172643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书